Same Drug, Two Versions And Prices, This Time For Lilly's Humalog

Lilly will launch an authorized generic version of Humalog at a 50% discount to the brand to assist patients without insurance or a high deductible, who don't benefit from rebates.

Insulin syringe and dollars money banknotes on a orange background - copy space - Image

Eli Lilly & Co. is the latest company to join the new trend of offering the same drug in two different versions to get around obstacles in the health care system that keep some patients from benefiting from rebates. The company announced March 4 that it will launch an authorized generic version of its short-acting insulin Humalog in the US at a 50% discount to the list price of the brand.

The authorized generic will be called Insulin Lispro – the generic name for the molecule – and will be available...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Drug Pricing

More from Scrip

Compass Pathways’ Antidepressant Advances In An Increasingly Tough Psychedelic Market

 
• By 

Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.

Eolo Pharma Advances In Obesity With Thermogenesis Approach

 
• By 

Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.

BioMarin’s Roctavian Continues to Shine In Hemophilia A Despite Commercial Woes

 

Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.